Allogeneic marrow transplantation in patients with acute and chronic myeloid leukemia: Influence of total body irradiation dose and graft versus host disease on relapse rate

V. Vitale, R. Corvo, P. Franzone, F. Frassoni, D. Scarpati, S. Barra, M. T. Van Lint

Research output: Contribution to journalArticlepeer-review

Abstract

From June 1981 to January 1988, 142 patients - 77 with acute myeloid leukemia (AML) and 65 with chronic myeloid leukemia (CML) - were treated with cyclophosphamide (60 mg/kg/d x 2 d) and total body irradiation (TBI) (9.90 Gy in 3 fractions in 3 d) before allogeneic bone marrow transplantation (BMT). All patients received marrow from an HLA identical sibling and were treated with cyclosporine A for graft versus host disease (GvHD) prophylaxis. An analysis of risk factors associated with leukemic relapse was carried out. A difference of ±18% between the calculated total dose TBI (9.90 Gy) and the actual dose measured (820-1250 cGy, mean 956 cGy) was observed and recorded according to in vivo measurements: 67 patients (36 AML and 31 CML) received

Original languageEnglish
Pages (from-to)207-216
Number of pages10
JournalBulletin du Cancer/Radiotherapie
Volume78
Issue number3
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Allogeneic marrow transplantation in patients with acute and chronic myeloid leukemia: Influence of total body irradiation dose and graft versus host disease on relapse rate'. Together they form a unique fingerprint.

Cite this